Skip to main content

Research Repository

Advanced Search

Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease

Mak, Anne Linde; Lee, Jenny; van Dijk, Anne-Marieke; Vali, Yasaman; Aithal, Guruprasad P.; Schattenberg, Jörn M.; Anstee, Quentin M.; Brosnan, M. Julia; Zafarmand, Mohammad Hadi; Ramsoekh, Dewkoemar; Harrison, Stephen A.; Nieuwdorp, Max; Bossuyt, Patrick M.; Holleboom, Adriaan G.

Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease Thumbnail


Authors

Anne Linde Mak

Jenny Lee

Anne-Marieke van Dijk

Yasaman Vali

Jörn M. Schattenberg

Quentin M. Anstee

M. Julia Brosnan

Mohammad Hadi Zafarmand

Dewkoemar Ramsoekh

Stephen A. Harrison

Max Nieuwdorp

Patrick M. Bossuyt

Adriaan G. Holleboom



Abstract

The prevalence and severity of non-alcoholic fatty liver disease (NAFLD) is increasing, yet adequately validated tests for care paths are limited and non-invasive markers of disease progression are urgently needed. The aim of this work was to summarize the performance of Pro-C3, a biomarker of active fibrogenesis, in detecting significant fibrosis (F ≥ 2), advanced fibrosis (F ≥ 3), cirrhosis (F4) and non-alcoholic steatohepatitis (NASH) in patients with NAFLD. A sensitive search of five databases was performed in July 2021. Studies reporting Pro-C3 measurements and liver histology in adults with NAFLD without co-existing liver diseases were eligible. Meta-analysis was conducted by applying a bivariate random effects model to produce summary estimates of Pro-C3 accuracy. From 35 evaluated reports, eight studies met our inclusion criteria; 1568 patients were included in our meta-analysis of significant fibrosis and 2058 in that of advanced fibrosis. The area under the summary curve was 0.81 (95% CI 0.77–0.84) in detecting significant fibrosis and 0.79 (95% CI 0.73–0.82) for advanced fibrosis. Our results support Pro-C3 as an important candidate biomarker for non-invasive assessment of liver fibrosis in NAFLD. Further direct comparisons with currently recommended non-invasive tests will demonstrate whether Pro-C3 panels can outperform these tests, and improve care paths for patients with NAFLD.

Citation

Mak, A. L., Lee, J., van Dijk, A.-M., Vali, Y., Aithal, G. P., Schattenberg, J. M., Anstee, Q. M., Brosnan, M. J., Zafarmand, M. H., Ramsoekh, D., Harrison, S. A., Nieuwdorp, M., Bossuyt, P. M., & Holleboom, A. G. (2021). Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines, 9(12), Article 1920. https://doi.org/10.3390/biomedicines9121920

Journal Article Type Article
Acceptance Date Dec 10, 2021
Online Publication Date Dec 15, 2021
Publication Date Dec 15, 2021
Deposit Date Jan 4, 2022
Publicly Available Date Jan 6, 2022
Journal Biomedicines
Electronic ISSN 2227-9059
Publisher MDPI
Peer Reviewed Peer Reviewed
Volume 9
Issue 12
Article Number 1920
DOI https://doi.org/10.3390/biomedicines9121920
Keywords General Biochemistry, Genetics and Molecular Biology; Medicine (miscellaneous)
Public URL https://nottingham-repository.worktribe.com/output/7163593
Publisher URL https://www.mdpi.com/2227-9059/9/12/1920

Files





You might also like



Downloadable Citations